Volume 9, Number 1—January 2003
Research
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
Gillian D. Sanders*
and Al V. Taira*
and Al V. Taira*Table 1
Health and economic outcomes of HPV vaccinationa
| Outcome | No vaccination | HPV vaccination |
|---|---|---|
| Cost, $ | 39,682 | 39,928 |
| Incremental cost, $ | 246 | |
| Life expectancy, yrs | 28.785 | 28.793 |
| Incremental life expectancy, days | 2.8 | |
| Quality-adjusted life expectancy, yrs | 27.720 | 27.731 |
| Incremental quality-adjusted life expectancy, days | 4.0 | |
| Incremental cost effectiveness | ||
| $/life year | 32,066 | |
| $/quality-adjusted life year | 22,755 |
aHPV, Human papillomavirus.
